FDA approves Johnson & Johnson’s nasal spray for depression as standalone treatment - CNBC
Spravato is now the first-ever standalone therapy for treatment-resistant depression, and is on its way to becoming a blockbuster product.
Search Group
Share To
Comments
About Screade
Screade® Inc. version f59620b, copyright 2016 - 2025
Blocked Users
Customize Dark Theme
Forgot your password?
Forgot your password?
Invite your friends
Please type emails of people you want to invite, we will send them invitation email on your behalf. Separate emails with comma if you want to invite multiple friends.
Comments